Charles River Laboratories International (NYSE:CRL) Updates FY 2025 Earnings Guidance

Key Points

• Charles River Laboratories International updated its FY 2025 earnings guidance, projecting an EPS of $9.900-$10.300 and revenue of $3.9 billion-$4.0 billion, which aligns closely with analyst expectations.
• Several investment firms have adjusted their ratings and price targets for CRL, with Barclays raising the target from $155.00 to $165.00 and Citigroup increasing its target from $150.00 to $200.00.
• Despite these positive updates, CRL stock saw a decline of 2.6% and currently has a market capitalization of $7.17 billion.

Charles River Laboratories International (NYSE:CRL - Get Free Report) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided EPS guidance of 9.900-10.300 for the period, compared to the consensus EPS estimate of 10.180. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays raised their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 7th. Wall Street Zen downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, September 21st. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $150.00 to $200.00 in a research report on Wednesday, July 9th. JPMorgan Chase & Co. raised their target price on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Finally, Evercore ISI upped their target price on Charles River Laboratories International from $180.00 to $190.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Six analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $177.07.

Charles River Laboratories International Stock Down 2.6%

CRL stock opened at $145.63 on Friday. The company has a market capitalization of $7.17 billion, a price-to-earnings ratio of -109.50, a price-to-earnings-growth ratio of 4.00 and a beta of 1.47. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $230.02. The firm's 50-day moving average is $159.76 and its two-hundred day moving average is $147.83.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $983.76 million. During the same period last year, the firm earned $2.80 EPS. The firm's revenue for the quarter was up .6% on a year-over-year basis. On average, analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares of the company's stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Large investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its stake in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company's stock worth $44,000 after acquiring an additional 145 shares in the last quarter. Osaic Holdings Inc. lifted its position in Charles River Laboratories International by 24.7% in the 2nd quarter. Osaic Holdings Inc. now owns 1,091 shares of the medical research company's stock worth $165,000 after buying an additional 216 shares in the last quarter. Humankind Investments LLC acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $210,000. Jones Financial Companies Lllp grew its holdings in shares of Charles River Laboratories International by 167.6% during the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock valued at $253,000 after acquiring an additional 1,074 shares in the last quarter. Finally, EP Wealth Advisors LLC acquired a new position in shares of Charles River Laboratories International in the second quarter worth $289,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.